Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study
Objective To develop personalized treatment strategies for maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Materials and Methods We analyzed data from ES-SCLC patients who achieved stable disease (SD) following initial chemotherapy combined with immunotherapy....
Saved in:
Main Authors: | Yi Peng MD, De Wu MD, Jing Tang MD, Xiaobing Li MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Cancer Control |
Online Access: | https://doi.org/10.1177/10732748251318383 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer
by: Jinbo Ma MD, et al.
Published: (2025-01-01) -
Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
by: Sandy El Bitar, et al.
Published: (2018-01-01) -
Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01) -
Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis
by: Xiaojun Yang, et al.
Published: (2022-01-01) -
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
by: Rangarirai Makuku, et al.
Published: (2021-01-01)